Podcasts about clinical cancer genetics

October is Breast Cancer Awareness Month. The Director of Clinical Cancer Genetics and Global Health at The University of Chicago Medicine, Dr. Funmi Olopade, talks about the latest research in breast cancer treatment and how Black women can recover and heal.

Every child inherits a set of “germline” DNA from each of their biological parents. At times there are also mutations that are passed down. This differs from what are referred to as “somatic” mutations that are only present in cancer cells, but not in every cell in the body. Environmental factors can also contribute to the development of cancers. Knowing your family history and genetic makeup can help in understanding overall cancer risk, recommended screening and prevention strategies, as well as treatment approaches if diagnosed with cancer. Guests: Ravi Sharaf, MD, MS, Director of Clinical Cancer Genetics at Weill Cornell Medicine Host: John Leonard, MD, a leading hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital

Meet Our Guest: Feyi Ayodele is the co-founder and CEO of CancerIQ, a fast-growing precision health platform that allows providers to identify, evaluate and manage entire patient populations based on individual genetic risk factors. In 2013, Ayodele co-founded CancerIQ after taking a sabbatical from the finance world to work alongside her mother, renowned medical oncologist Olufunmilayo Olopade, in the Center for Clinical Cancer Genetics at University of Chicago.  Key Insights: CancerIQ's mission is to make sure more people have access to the right genetic testing services and the right preventive care so cancer can be caught early or the risk can be eliminated altogether. ● From Finance to Healthcare. After starting her career in financial services, she went to Wharton for business school and then felt compelled to take the entrepreneurship path in healthcare.● Early Detection. CancerIQ makes it easy for health systems to personalize cancer prevention and early detection. The company's mission is to make genetic information more accessible and actionable, to empower patients and clinicians in the fight against cancer.● Be a Case Study. Feyi shares insights on the importance of being a successful case study for underrepresented groups in leadership positions. This episode is hosted by CarlaDenise Edward, Ph.D., Strategic Advisor.Relevant Links: Read more about FeyiAbout CancerIQ

Cancer: why we get it, the genetics that may cause it and ways to avoid it with Hematologist-Oncologist and Clinical Cancer Genetics specialist Dr. Colleen Yavarow on MD for Moms with host Dr. Carly Snyder

Cancer: why we get it, the genetics that may cause it and ways to avoid it with Hematologist-Oncologist and Clinical Cancer Genetics specialist Dr. Colleen Yavarow on MD for Moms with host Dr. Carly Snyder

Guest: Olufunmilayo (Funmi) Olopade, MD, FACP Host: Maurice Pickard, MD Host Dr. Maurice Pickard welcomes Olufunmilayo (Funmi) Olopade, MD, FACP, Walter L. Palmer Distinguished Service Professor of Medicine & Human Genetics, Associate Dean for Global Health, and Director of Center for Clinical Cancer Genetics at the University of Chicago Medicine, Chicago, IL. Dr. Olopade reviews the latest information and best practices in establishing an interdisciplinary program in improving chronic disease treatment worldwide. She reviews challenges and progress toward providing better education, research and training, and service infrastructures addressing global health issues within the United States and around the world.

Guest: Olufunmilayo (Funmi) Olopade, MD, FACP Host: Maurice Pickard, MD Host Dr. Maurice Pickard welcomes Olufunmilayo (Funmi) Olopade, MD, FACP, Walter L. Palmer Distinguished Service Professor of Medicine & Human Genetics, Associate Dean for Global Health, and Director of Center for Clinical Cancer Genetics at the University of Chicago Medicine, Chicago, IL. Dr. Olopade reviews the latest information and best practices in establishing an interdisciplinary program in improving chronic disease treatment worldwide. She reviews challenges and progress toward providing better education, research and training, and service infrastructures addressing global health issues within the United States and around the world.

Host: Maurice Pickard, MD Guest: Olufunmilayo (Funmi) Olopade, MD, FACP Host Dr. Maurice Pickard welcomes Dr. Funmi Olopade, Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics, Director of the Hematology/Oncology Fellowship Program, and Director of the Center for Clinical Cancer Genetics at the University of Chicago. Dr. Olopade discusses disparities in health outcomes for black women with breast cancer. Dr. Olopade is an expert in cancer risk assessment and individualized treatment for the most aggressive forms of breast cancer, having developed novel management strategies based on an understanding of the altered genes in individual patients. She stresses comprehensive risk reduction and prevention strategies in high-risk populations, as well as earlier detection through advanced imaging technologies.

Host: Maurice Pickard, MD Guest: Olufunmilayo (Funmi) Olopade, MD, FACP Host Dr. Maurice Pickard welcomes Dr. Funmi Olopade, Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics, Director of the Hematology/Oncology Fellowship Program, and Director of the Center for Clinical Cancer Genetics at the University of Chicago. Dr. Olopade discusses disparities in health outcomes for black women with breast cancer. Dr. Olopade is an expert in cancer risk assessment and individualized treatment for the most aggressive forms of breast cancer, having developed novel management strategies based on an understanding of the altered genes in individual patients. She stresses comprehensive risk reduction and prevention strategies in high-risk populations, as well as earlier detection through advanced imaging technologies.

Maureen Mork, MS, CGC, Certified Genetic Counselor, Clinical Cancer Genetics

Maureen Mork, MS, CGC, Certified Genetic Counselor, Clinical Cancer Genetics

Most women have a 10-11% lifetime risk of developing breast cancer by age 70. However, women with a BRCA1 or BRCA2 mutation have up to an 80% risk of developing breast cancer in their lifetime. Dr. Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center, says that’s why it’s important to evaluate family history carefully. In this lecture, Dr. Arun discusses breast cancer risk management options, including screening, chemoprevention, and surgery, for patients with a BRCA1 or BRCA2 mutation.

Most women have a 10-11% lifetime risk of developing breast cancer by age 70. However, women with a BRCA1 or BRCA2 mutation have up to an 80% risk of developing breast cancer in their lifetime. Dr. Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center, says that’s why it’s important to evaluate family history carefully. In this lecture, Dr. Arun discusses breast cancer risk management options, including screening, chemoprevention, and surgery, for patients with a BRCA1 or BRCA2 mutation.

Banu Arun, M.D., Professor, Department of Breast Medical Oncology, Co-Medical Director, Clinical Cancer Genetics

Banu Arun, M.D., Professor, Department of Breast Medical Oncology, Co-Medical Director, Clinical Cancer Genetics

Banu Arun, M.D., Professor, Department of Breast Medical Oncology, Co-Medical Director for Clinical Cancer Genetics

Banu Arun, M.D., Professor, Department of Breast Medical Oncology, Co-Medical Director for Clinical Cancer Genetics

How often you should get tested for breast cancer depends on your chances for getting the disease. If you are at increased risk for breast cancer, you may need to start screening exams at an earlier age, get additional tests or be tested more often. Dr. Banu Arun, Associate Professor of Breast Medical Oncology and Clinical Cancer Prevention, and Co-Director of Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center presents an overview of breast cancer risk management.

Diana Turco, a Certified Genetic Counselor at MD Anderson’s Clinical Cancer Genetics discusses whether or not genetic testing is right for you. Approximately 5-10% of cancer is inherited. Individuals who have a genetic predisposition for developing cancer will have a far higher chance of developing cancer within their lifetime and at an earlier age. Learn more about genetic testing and counseling.

Learn when your family history places you at increased risk for breast cancer. Dr. Banu Arun, Associate Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center and Diana Turco, Certified Genetic Counselor in Clinical Cancer Genetics, answer common questions regarding hereditary risk factors for breast cancer. Dr. Jennifer Litton, Assistant Professor of Breast Medical Oncology, at The University of Texas MD Anderson Cancer Center moderates the discussion.

Diana Turco, a Certified Genetic Counselor at MD Anderson’s Clinical Cancer Genetics discusses whether or not genetic testing is right for you. Approximately 5-10% of cancer is inherited. Individuals who have a genetic predisposition for developing cancer will have a far higher chance of developing cancer within their lifetime and at an earlier age. Learn more about genetic testing and counseling.

Dr. James Ford, Associate Professor of Medicine and Genetics at the Stanford University School of Medicine, discusses possibilities for using genetic testing to predict and manage the risks of certain cancers. (September 17, 2008)